Swiss pharmaceutical company Novartis, which owns Fort Worth-based Alcon Labs, reported a 6.7 percent increase in first-quarter profit Wednesday, boosted by new products and emerging markets.Novartis says its net profit rose to $2.42 billion from $2.27 billion in the same period last year despite declining sales of its blockbuster heart drug Diovan, which lost U.S. patent protection last year.The company said the increase -- a turnaround from the 18 percent earnings drop in the first quarter of 2012 -- reflects new product launches such as Gilenya for multiple sclerosis and Afinitor for cancer; strength in emerging markets; and European Union and U.S. drug approvals to offset patent expirations.The new drugs added $4.2 billion in revenue, almost a third of sales, making up for an estimated $500 million in losses during the quarter because of patent expirations. Overall, sales increased 2 percent to $14 billion, matching the average estimate.Sales at Alcon Labs grew by only 1 percent, to $2.6 billion, as the surgical equipment sector was affected by a slowdown in global cataract procedures. But operating income for the eye-care unit increased by 13 percent, benefiting from productivity improvements and cost containment."All divisions were strong with the exception of Alcon, which was hampered by sluggish revenues in the surgical business," Andrew Baum, a London-based analyst at Citigroup, said in a note to clients. "The surprising departure of the well-respected Novartis CFO Jon Symonds is likely to dominate investor attention."Novartis unexpectedly announced that Symonds, 54, is being replaced as chief financial officer by Harry Kirsch, 48, the finance head for the pharmaceutical division.The quarter was marked by the controversy over Novartis' outgoing board chairman, Daniel Vasella, who touched off widespread anger for his whopping severance package of $77 million -- pay he later declined.Also Wednesday, Novartis disclosed that its new chairman, Joerg Reinhardt, will be paid 3.8 million francs, split between cash and stock, and will receive 2.6 million euros for lost compensation from his former employer. It also said Ulrich Lehner will receive about 790,000 francs in cash and stock for serving as interim chairman from Feb. 22 until July 31.On Tuesday, the U.S. government filed a healthcare fraud lawsuit against Novartis in New York, saying it gave kickbacks to pharmacies to switch transplant patients from competitors' drugs to its own.The suit, which says the company's actions caused the public to pay tens of millions of dollars for kickback-tainted drugs, seeks unspecified damages and civil penalties. Novartis, which disputes the claims and will defend itself, settled fraud charges based on kickbacks less than three years ago.This report includes material from The Associated Press and Bloomberg News.